公开(公告)号：US20150017184A1

公开(公告)日：2015-01-15

申请号：US14499691

申请日：2014-09-29

Applicant: KIRIN-AMGEN, INC.

Inventor： Dingjiang Liu ,  Holly Zhuohong Huang ,  David Andrew Martin ,  Christopher Boyd Russell ,  David H. Salinger ,  Scott Walter Baumgartner ,  Christopher Engres

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K39/39591 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

Abstract translation: 本公开涉及用于治疗疾病的AM-14药物制剂和治疗剂量方案。

公开(公告)号：US20180346583A1

公开(公告)日：2018-12-06

申请号：US16053564

申请日：2018-08-02

Applicant: Kirin-Amgen, Inc.

Inventor： Dingjiang Liu ,  Holly Zhouhong Huang ,  David Andrew Martin ,  Christopher Boyd Russell ,  David H. Salinger ,  Scott Walker Baumgartner ,  Christopher Endres

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00

Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

公开(公告)号：US10166189B2

公开(公告)日：2019-01-01

申请号：US15011229

申请日：2016-01-29

Applicant: AMGEN INC.

Inventor： William J. Callahan ,  Richard L. Remmele, Jr. ,  Gayathri Ratnaswamy ,  Ramil F. Latypov ,  Dingjiang Liu

IPC: A61K39/395 ,  A61K9/19 ,  A61K38/10 ,  A61K38/16 ,  A61K47/22 ,  A61K47/26

Abstract: The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.

公开(公告)号：US10072085B2

公开(公告)日：2018-09-11

申请号：US14499691

申请日：2014-09-29

Applicant: KIRIN-AMGEN, INC.

Inventor： Dingjiang Liu ,  Holly Zhuohong Huang ,  David Andrew Martin ,  Christopher Boyd Russell ,  David H. Salinger ,  Scott Walter Baumgartner ,  Christopher Endres

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/39591 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present disclosure relates to ΛM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.